EAGLE PHARMACEUTICALS INC. - COMMON STOCK

Eagle Pharmaceuticals Reports Second Quarter 2023 Results

08 Aug 2023 05:50:54 By Nasdaq GlobeNewswire

Eagle Pharmaceuticals to Host Second Quarter 2023 Financial Results on August 8, 2023

01 Aug 2023 05:50:00 By Nasdaq GlobeNewswire

Eagle Pharmaceuticals Raises 2023 Adjusted non-GAAP EPS¹ Guidance

31 Jul 2023 05:50:00 By Nasdaq GlobeNewswire

Eagle Pharmaceuticals Provides Business Update and Reiterates 2023 Guidance

15 Jun 2023 05:50:00 By Nasdaq GlobeNewswire

Eagle Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) and Fast-Track Designation for CAL02, Providing Five-Year Exclusivity Extension

14 Jun 2023 05:50:00 By Nasdaq GlobeNewswire

Eagle Pharmaceuticals Announces Acceptance of Two Abstracts at the Society for Academic Emergency Medicine (SAEM) Annual Meeting

11 May 2023 05:50:00 By Nasdaq GlobeNewswire

Eagle Pharmaceuticals Reports First Quarter 2023 Results

09 May 2023 05:50:00 By Nasdaq GlobeNewswire

Eagle Pharmaceuticals Granted Unique J-Code for Byfavo®¹ (remimazolam for injection) from CMS

01 May 2023 05:50:00 By Nasdaq GlobeNewswire

Eagle Pharmaceuticals to Host First Quarter 2023 Financial Results on May 9, 2023

27 Apr 2023 15:30:00 By Nasdaq GlobeNewswire

Eagle Pharmaceuticals Reaches Settlement Agreement with Dr. Reddy’s Laboratories Inc. and Dr. Reddy’s Laboratories Ltd. Related to BENDEKA® (bendamustine hydrochloride)

05 Apr 2023 05:50:00 By Nasdaq GlobeNewswire

Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Results

13 Mar 2023 05:50:00 By Nasdaq GlobeNewswire

Eagle Pharmaceuticals to Present at the Barclays Global Healthcare Conference

09 Mar 2023 15:10:00 By Nasdaq GlobeNewswire

Eagle Pharmaceuticals to Host Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023

03 Mar 2023 05:50:00 By Nasdaq GlobeNewswire

Eagle Pharmaceuticals Provides Business Update and Guidance for 2023

10 Jan 2023 13:00:10 By Nasdaq GlobeNewswire

Eagle Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

21 Dec 2022 15:30:00 By Nasdaq GlobeNewswire

Eagle Pharmaceuticals Receives FDA Approval for Additional Indication for PEMFEXY® in Combination with Pembrolizumab and Platinum Chemotherapy

19 Dec 2022 05:50:00 By Nasdaq GlobeNewswire

Eagle Pharmaceuticals Reaches Settlement Agreement with Accord Healthcare, Inc. Related to BENDEKA® (bendamustine hydrochloride)

12 Dec 2022 05:50:00 By Nasdaq GlobeNewswire

Eagle Pharmaceuticals’ Investor Day to Focus on Acute Care Products and Pipeline Programs; Tuesday, December 6, 2022, at 8:00am ET at the Lotte New York Palace

01 Dec 2022 05:50:00 By Nasdaq GlobeNewswire

Eagle Pharmaceuticals’ Investor Day to Feature World-Renowned KOLs on Tuesday, December 6, 2022, at the Lotte New York Palace Hotel

16 Nov 2022 05:50:00 By Nasdaq GlobeNewswire

Eagle Pharmaceuticals Announces FDA Acceptance of Investigational New Drug Application for CAL02, a Novel First-in-Class Broad-Spectrum Anti-Virulence Agent for the Adjunct Treatment of Severe Community-Acquired Bacterial Pneumonia

14 Nov 2022 05:50:00 By Nasdaq GlobeNewswire